For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
TB4 is a naturally occurring 43-amino acid peptide involved in actin regulation, cell migration, angiogenesis, and tissue repair. TB-500 is a synthetic 7-amino acid fragment (aa 17-23) that retains the core actin-binding domain. TB4 has Phase 2 human clinical data in ophthalmology (3 trials, zero adverse events) and dermal wound healing. TB-500 has no human clinical trial data. The most clinically sought-after application, musculoskeletal repair, has no human evidence for either compound. Both are WADA prohibited under S2 since 2011. The Phase 3 SEER-3 trial of RGN-259 (ophthalmic TB4) missed its primary endpoint in March 2026.
All human clinical evidence pertains to TB4 (full-length, 43 amino acids), not TB-500 (the 7-amino acid synthetic fragment). There are no human clinical trials for TB-500 specifically. The nomenclature distinction is the most important thing to understand before interpreting any evidence in this profile.
FDA regulatory update (April 2026): TB-500 was removed from Category 2 effective April 22, 2026, because the original nominations were withdrawn. This is a procedural change and does not authorize compounding. The FDA Pharmacy Compounding Advisory Committee is scheduled to review TB-500 on July 23, 2026 for possible inclusion on the 503A Bulks List. Until that review is complete and a determination is made, licensed compounding pharmacies remain unable to produce TB-500 under the standard framework.
Phase 3 development update (March 2026): The SEER-3 Phase 3 trial of RGN-259 in European neurotrophic keratitis patients failed to meet its primary endpoint. HLB Therapeutics attributed the failure to a stronger-than-expected placebo effect in the control arm. The US Phase 3 trial (SEER-2) is ongoing. This negative result does not invalidate the Phase 2 data, but it demonstrates that Phase 2 success does not guarantee Phase 3 replication and introduces genuine uncertainty about the ophthalmic regulatory pathway.
WADA status: both TB4 and TB-500 have been on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, and Related Substances) since 2011. TB-500 is explicitly named alongside Thymosin-beta-4 and its derivatives. Any athlete subject to doping control faces sanctions for use of either compound, regardless of therapeutic intent. No Therapeutic Use Exemption pathway is available.
Thymosin Beta-4 (TB4) is a naturally occurring 43-amino acid peptide found in virtually all tissues of the human body, with particularly high expression in platelets, macrophages, the thymus, spleen, brain, liver, kidney, testis, myocardium, and leukocytes. It is one of the most abundant intracellular peptides in eukaryotic cells and plays a fundamental role in actin cytoskeleton regulation.
After tissue injury, TB4 is rapidly released by platelets, macrophages, and many other cell types to protect cells from further damage and coordinate the repair response. Its core function is sequestering G-actin (globular actin monomers), which regulates actin filament polymerization and thereby controls cell migration, proliferation, and differentiation. This makes TB4 a fundamental coordinator of the wound healing response at the cellular architecture level.
TB-500 is the synthetic replication of the active actin-binding fragment of TB4, specifically amino acids 17 to 23 (the sequence Ac-LKKTETQ). This 7-amino acid region contains the core actin-binding domain responsible for triggering angiogenesis and hair follicle activation. Its development has been driven by the hypothesis that this fragment captures the most therapeutically relevant activity of the full peptide in a smaller, more synthetically tractable molecule.
The clinical development of TB4 has been pursued primarily by RegeneRx Biopharmaceuticals under the trade name RGN-259 (ophthalmic formulation), now developed through the US joint venture ReGenTree LLC with HLB Therapeutics. The compound has completed multiple Phase 2 clinical trials and has Phase 3 trials underway in ophthalmology, making ophthalmic healing the most clinically advanced application. The Phase 3 SEER-3 European trial missed its primary endpoint in March 2026; the US SEER-2 trial is ongoing.
TB4's mechanism centers on actin cytoskeleton regulation. The key interaction is with G-actin (globular actin monomers): TB4 sequesters free G-actin by binding it at a 1:1 ratio, regulating the pool of actin available for polymerization into F-actin filaments. By controlling this balance, TB4 governs whether cells extend migration-driving protrusions (lamellipodia, filopodia), whether they contract, and whether they divide.
In the context of injury, this actin regulation translates into coordinated repair: endothelial cells migrate toward wounds and form new blood vessels (angiogenesis); epithelial cells migrate to cover denuded surfaces (re-epithelialization); and stem and progenitor cells are mobilized from bone marrow and tissue niches to regenerate damaged structures. TB4 also decreases the number of myofibroblasts in wounds, the cells responsible for contractile scar formation, resulting in reduced fibrosis and better-quality healing.
Secondary mechanisms include: activation of the focal adhesion kinase (FAK)/paxillin complex to drive cell survival and motility; Akt activation with wide-ranging effects on cell growth, survival, and motility; anti-fibrotic effects via TGFbeta/Smad pathway inhibition (directly relevant to liver and kidney fibrosis applications); and indirect VEGFR2 activation contributing to angiogenesis.
TB-500, as the synthetic aa 17-23 fragment, retains the core actin-binding domain activity and has shown similar tissue repair effects in preclinical models, but lacks the full signaling repertoire of the complete 43-amino acid molecule. This mechanistic distinction is directly relevant to interpreting which evidence applies to which compound: preclinical studies sometimes use the full peptide and sometimes the fragment, and the results may not be fully interchangeable.
Phase 2 RCT (Sosne and Ousler 2015, n=72, 28 days, dry eye CAE model): neither primary endpoint (ocular discomfort or inferior corneal staining) reached statistical significance at the exact primary timepoint, but discomfort scores on day 28 were reduced by 27% in TB4-treated subjects versus placebo, and central and superior corneal staining showed statistically significant improvement. No adverse events were observed.
Separate Phase 2 double-blind RCT in severe dry eye: eye discomfort decreased by 35.1% in the TB4 group and corneal fluorescein staining improved by 59.1%. Zero adverse events across all three Phase 2 ophthalmic trials combined: a safety record that is unusual in clinical drug development.
SEER-1 Phase 3 (neurotrophic keratitis, approximately 18 patients): 60% of RGN-259-treated patients achieved complete corneal healing. Primary endpoint trending toward statistical significance. Served as basis for initiating SEER-2 and SEER-3.
SEER-3 Phase 3 (European, approximately 70 NK patients): missed primary endpoint March 2026. Stronger-than-expected placebo effect in control arm. SEER-2 (US) ongoing.
More than 1,700 subjects have received RGN-259 across all trials indicating various degrees of efficacy in both dry eye and neurotrophic keratitis.
Ophthalmology is TB4's most clinically advanced application: the most rigorous human trial design, zero adverse events across all Phase 2 trials, and a clear regulatory pathway. The SEER-3 Phase 3 failure in March 2026 is a genuine setback that must be acknowledged. A stronger-than-expected placebo effect is a recognized challenge in dry eye and corneal trials due to the intensive monitoring and artificial tear use during trial participation. The US SEER-2 trial is ongoing and its results will be decisive for the regulatory pathway. The pattern of missing primary endpoints at exact timepoints while showing strong secondary outcomes suggests trial design challenges rather than mechanism failure, but Phase 3 replication failure is always a meaningful signal that requires honest disclosure.
The foundational Malinda et al. (1999) study demonstrated wound healing was 42% improved compared to saline control by day 4, reaching 61% improvement by day 7. After 14 days, collagen fiber bundles in treated wounds were thicker and longer with less scarring.
Phase 2 pressure ulcer clinical trial (TB4): 42% improvement in re-epithelialization versus saline at day 4, 61% by day 7, and an 11% greater improvement in wound bed preparation in TB4-treated patients. These results replicate the preclinical findings in humans.
Venous stasis ulcers Phase 2: mean healing time 39 days with TB4 versus 71 days for placebo: a 45% reduction in healing time. Small study size prevented statistical confirmation despite the large effect size.
Guarnera 2010 (n=73, 8 European sites, topical TB4 for chronic leg ulcers): approximately 25% complete healing in 3 months at the 0.03% dose, with stronger response in smaller wounds. Acceptable safety profile.
The anti-myofibroblast mechanism (Ehrlich and Hazard 2010): TB4 reduces myofibroblast numbers in wounds, directly reducing scar formation and fibrosis, explaining why TB4 heals wounds with better cosmetic and functional outcomes than untreated healing.
Among the strongest areas of TB4 clinical evidence outside ophthalmology. The Phase 2 wound healing data is compelling: the 39 vs 71 day venous stasis ulcer result represents a clinically meaningful and large absolute effect. The limitation is statistical underpowering across existing trials. Larger Phase 3 dermal wound trials are scientifically well-justified and represent the clearest development pathway outside ophthalmology. The anti-myofibroblast mechanism is a distinctive differentiator: better-quality healing, not just faster healing.
Smart et al. (2007) Nature: systemic TB4 administration in adult mice increased the number of capsulin-positive epicardial progenitor cells in the coronaries, atrioventricular valves, and epicardium, and crucially, this activation was independent of hypoxic injury. TB4 is capable of reactivating embryonic cardiac progenitor processes in the adult heart through systemic administration. This finding is the scientific basis for TB4 cardiac development.
At the cellular level, TB4 binds and alters cytoskeletal actin filaments in myocardial and endothelial cells, regulating migration of epicardial progenitors. It activates the focal adhesion complex, leading to Akt activation with wide-ranging effects on cell growth, survival, and motility.
Maar et al. (2021) confirmed that TB4 reactivates embryonic processes in the adult heart, a finding with implications for cardiac regenerative medicine.
Zhu et al. (2016) pilot study in acute STEMI patients (n=18): used autologous endothelial progenitor cells pre-treated with TB4 before transplantation, rather than TB4 administered directly. Reported favorable safety outcomes. This is one of the first human attempts to leverage TB4's progenitor mobilization for cardiac repair, but it is not a trial of direct TB4 administration.
One of the most scientifically exciting application areas in TB4 research, anchored by a landmark Nature publication. The human evidence is extremely early: a single pilot safety/feasibility study in 18 patients that used TB4-treated progenitor cells rather than direct TB4 administration. The gap between compelling preclinical biology and validated human outcomes is wide. Well-designed cardiac RCTs using direct TB4 administration are needed to determine whether the preclinical results translate to humans.
Spurney et al. (2010): in a 6-month study, thymosin beta-4 administration improved skeletal muscle fiber regeneration in dystrophin-deficient mice, a model of Duchenne muscular dystrophy.
In rat incision wound models, TB-500-treated animals showed minimal scarring and significantly narrower wounds compared to controls.
In tendon and ligament pathology preclinical models, both TB4 and TB-500 have shown significant improvement in tissue repair across multiple independent research groups. Mechanism: TB4 promotes tendon healing by enhancing tendon outgrowth, improving cell survival, and stimulating cell migration through FAK/paxillin and actin remodeling pathways. TB4 also modulates growth factors including FGF and VEGF, supporting vascularization of healing tendon tissue critical for long-term repair quality.
The preclinical data is consistent and robust across multiple tissue types and multiple independent research groups, which increases confidence in the mechanism despite the absence of human data.
The preclinical data in musculoskeletal repair is consistent and robust. This is the most clinically sought-after application for TB-500 specifically, driven by the sports medicine and athletic performance community. However, no dedicated human musculoskeletal trials exist for either TB4 or TB-500. The gap between animal models and validated human evidence remains entirely uncrossed. This is the most significant disconnect between clinical demand and clinical evidence in the entire TB4/TB-500 research landscape. A well-designed Phase 1/2 human trial in tendon or ligament repair would be the single most transformative piece of research for this compound class.
Zhang et al. reported that TB4 treatment inhibited the TGFbeta-1/NF-kB signaling pathway in TBI models, affecting both neuroprotection (limiting acute injury) and neurorestoration (promoting recovery). In the experimental autoencephalomyelitis mouse MS model, TB-500 treatment produced functional neurological improvement. Morris et al. (2010) demonstrated improved functional neurological outcomes in a rat embolic stroke model.
The neuroprotective mechanisms operate through multiple potential pathways: modulation of CNS inflammatory responses, promotion of neuronal survival via Akt activation, and enhancement of axonal regeneration and synaptic plasticity through actin cytoskeletal regulation. Actin dynamics are fundamental to axonal growth cones and dendritic spine remodeling, providing mechanistic plausibility for CNS effects.
Mechanistically credible: actin dynamics are fundamental to synaptic plasticity and axonal growth. The human evidence is entirely absent. All neuroprotection findings are preclinical. No human neurology trials exist for TB4 or TB-500 in any CNS indication. This remains a promising but very early-stage application area.
Chen et al. demonstrated that TB4 reduced TGF-beta-1, TGFbetaR II, Smad2, and Smad3 expression in liver tissue in a bile duct ligation cholestatic fibrosis model, and reduced TGFbetaR II expression in human hepatic stellate cells, directly implicating the TGFbeta/Smad signaling pathway (the master regulator of fibrosis) as TB4's anti-fibrotic mechanism.
Shah et al. (2018) confirmed that TB4 inhibits hepatic stellate cell activation through its actin-binding domain: a cell-type-specific anti-fibrotic mechanism targeting the primary effector cells of liver fibrosis.
Liang et al. provided correlational human data: TB4 expression negatively correlated with inflammation and fibrosis scores in chronic hepatitis B with NAFLD, consistent with an endogenous anti-fibrotic role. This is human correlational data, not interventional trial data.
TGFbeta/Smad inhibition is one of the most established anti-fibrotic mechanisms in hepatology. TB4's mechanistic action at this pathway is well-characterized in preclinical models. The correlational human data provides a biologically plausible signal but is not interventional evidence. No anti-fibrotic clinical trials have been initiated. This is a scientifically credible but unvalidated application requiring dedicated clinical development.
Gao et al. (2015) demonstrated that exogenous TB4 induced the transition of hair follicles from the resting telogen phase into the active anagen (growth) phase in mice. The mechanism involves improved follicular vascularization and the mobilization of stem cells in the hair follicle bulge region. The active fragment at aa 17 to 23 of TB4, which is exactly the sequence replicated by TB-500, triggers angiogenesis and growth of hair follicles.
Intriguing biological mechanism but evidence is limited to a single mouse study with no independent replication and no human data. This is the weakest use case from an evidence perspective and should be characterized as speculative in the absence of human trials.
FDA regulatory status of TB-500 is in transition: removed from Category 2 April 2026 (procedural), PCAC review July 23, 2026 for possible 503A Bulks List inclusion. Both TB4 and TB-500 remain WADA prohibited under S2 at all times. No formal pharmacokinetic study has been published for either TB4 or TB-500 by any administration route: the most significant data gap in the entire development program. Research-grade quality standards: HPLC purity 98% or above, full 43-AA sequence confirmation for TB4 by mass spec, TB-500 sequence verification confirming Ac-LKKTETQ with acetylated N-terminus, endotoxin below 1 EU/mg for injectable preparations.
TB4/TB-500 vs BPC-157 (tissue repair comparison): these two are the most commonly paired in research community discussions, both primarily sought for musculoskeletal repair. They operate through distinct and complementary mechanisms: TB4/TB-500 works through actin cytoskeletal regulation, FAK/paxillin signaling, and stem/progenitor cell mobilization; BPC-157 works through VEGFR2-driven angiogenesis, the NO system, and growth hormone receptor upregulation. Neither has validated human musculoskeletal trial data. TB4 has Phase 2 human evidence in wound healing and ophthalmology (with a Phase 3 setback in March 2026); BPC-157 has Phase II IBD exposure in Croatia and a 2025 HSS Journal systematic review. Both are WADA prohibited.
TB4/TB-500 vs Thymosin Alpha-1 (namesake comparison): the Thymosin name creates a common misconception. TB4 and Tα1 were isolated from the same thymic extract but are structurally and mechanistically unrelated. Tα1 is an immune modulator; TB4 is an actin cytoskeleton regulator. Tα1 has approximately 30 or more clinical trials, approvals in 35 or more countries, and 11,000 or more human subjects. They are complementary compounds with no indication overlap.
The most informative human safety data for TB4 comes from a dedicated Phase 1 randomized controlled safety trial: 40 healthy adults received intravenously-administered doses ranging from 42 to 1,260 mg. The compound appeared well tolerated across this entire dose range with no dose-limiting toxicities observed.
Three Phase 2 ophthalmic clinical trials reported zero adverse events across all participants, a safety record that is unusual in clinical drug development.
Rare adverse effects reported in research contexts include redness and pain at the injection site. No pancreatitis, hepatotoxicity, or cardiac adverse signals have been identified in any TB4 clinical trial.
Safety data that exists applies to pharmaceutical-grade TB4 in clinical settings, not to TB-500 fragments from unregulated research peptide suppliers, which carry standard impurity and immunogenicity risks. No long-term human safety data exists for either compound by any systemic route.
WADA and regulatory status: both TB4 and TB-500 are WADA prohibited. The FDA regulatory status of TB-500 is under review (PCAC July 23, 2026). These are not safety signals per se but are critical regulatory facts for any researcher or athlete considering these compounds.
TB4/TB-500 occupies a unique and somewhat complicated position in the research landscape as of May 2026.
TB4 (full-length) has genuine Phase 2 clinical evidence in ophthalmology and wound healing: real, human, controlled data with meaningful effect sizes. The ophthalmic application through RegeneRx/ReGenTree has been the clearest clinical development pathway. The Phase 3 SEER-3 failure in March 2026 is a genuine setback that cannot be minimized: a Phase 3 trial missed its primary endpoint in European neurotrophic keratitis patients. The US SEER-2 trial is ongoing and its results will be decisive. A drug that showed strong Phase 2 results but mixed Phase 3 results is in an uncertain regulatory position that is meaningfully different from where this profile stood at v1.0 in March 2026.
TB-500 as the synthetic fragment has no human clinical trial data of its own. The FDA Category 2 removal in April 2026 is a procedural change pending a July 2026 PCAC review: it does not restore compounding authorization in the interim. Both compounds remain WADA prohibited under S2 since 2011.
The defining tension in this profile remains unchanged: the enormous gap between the most sought-after application (musculoskeletal and tendon repair in sports medicine) and the near-total absence of human evidence for it. A well-designed Phase 1/2 musculoskeletal trial would be the single most transformative data event for TB4/TB-500's clinical standing.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use